CONMED Corp (CNMD): who owns it and who trades it
As of Nov 16, 2026, CNMD insiders reported 1 open-market sale worth $10.6K and no purchases in the last 12 months, with 100% of the sale value made under pre-set 10b5-1 plans. The largest seller was Richard Glaze (Chief Information Office), with $10.6K. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling CONMED
From the latest filingsOverall: more buying than selling. Famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns CNMD
245 funds and institutions reported CNMD shares worth $1.2B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is BlackRock, Inc. with 15.6%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 4.82M | 15.63% | $158M | -0% |
| Earnest Partners LLC | 2.51M | 8.13% | $82M | -3% |
| Vanguard Portfolio Management LLC | 2.19M | 7.10% | $71.6M | +5% |
| Fuller & Thaler Asset Management, Inc. | 1.58M | 5.12% | $51.7M | -4% |
| State Street Corp | 1.42M | 4.60% | $46.4M | +2% |
| Vanguard Capital Management LLC | 1.36M | 4.40% | $44.4M | -2% |
| Bank of America Corp | 1.34M | 4.35% | $43.9M | -4% |
| Dimensional Fund Advisors LP | 1.32M | 4.27% | $43.1M | -5% |
| California State Teachers Retirement System | 1.08M | 3.50% | $33M | +2645% |
| Sei Investments Co | 988,151 | 3.20% | $32.3M | -2% |
| Invenomic Capital Management LP | 842,162 | 2.73% | $27.6M | -10% |
| Capital Research Global Investors | 823,636 | 2.67% | $27M | -11% |
| Geode Capital Management, LLC | 790,138 | 2.56% | $25.9M | +6% |
| Two Sigma Investments, LP | 728,976 | 2.36% | $23.9M | -7% |
| Allspring Global Investments Holdings, LLC | 618,447 | 2.01% | $20.3M | +6% |
| Cooke & Bieler LP | 573,498 | 1.86% | $18.8M | -42% |
| Paradigm Capital Management Inc | 538,245 | 1.75% | $17.6M | – |
| Arrowstreet Capital, Limited Partnership | 476,885 | 1.55% | $15.6M | +14% |
| Charles Schwab Investment Management Inc | 471,022 | 1.53% | $15.4M | -2% |
| Sixth Street Partners Management Company, L.P. | 471,022 | 1.53% | $15.4M | – |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, CNMD insiders reported $0 of open-market purchases and $10.6K of sales. 100% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 21, 2025 | Richard Glaze | Chief Information Office | Sale plan | 257 | $41.21 | $10.6K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Richard Glaze | Chief Information Officer | – | $10.6K | Nov 21, 2025 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
CNMD short interest
Moderate short interest. 6.2% of CNMD shares are sold short: about 1 share in 16. Over the last 12 reports the number of shares short went down 19%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 1.86M CNMD shares were sold short, 6.2% of the shares outstanding, down 2.7% from the report before. At the average daily volume of 433,661 shares, buying them all back would take about 4.3 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 1.86M | 6.24% | -3% | 433,661 | 4.3 |
| Oct 15, 2026 | 1.91M | 6.38% | -2% | 408,109 | 4.7 |
| Sep 30, 2026 | 1.96M | 6.53% | -9% | 373,796 | 5.2 |
| Sep 15, 2026 | 2.14M | 7.14% | -6% | 292,435 | 7.3 |
| Aug 31, 2026 | 2.26M | 7.56% | -2% | 315,282 | 7.2 |
| Aug 14, 2026 | 2.32M | 7.74% | +4% | 463,121 | 5.0 |
| Jul 31, 2026 | 2.23M | 7.46% | -4% | 644,227 | 3.5 |
| Jul 15, 2026 | 2.33M | 7.55% | -8% | 943,826 | 2.5 |
| Jun 30, 2026 | 2.53M | 8.21% | +18% | 712,370 | 3.6 |
| Jun 15, 2026 | 2.15M | 6.98% | -8% | 550,737 | 3.9 |
| May 29, 2026 | 2.34M | 7.60% | +2% | 433,890 | 5.4 |
| May 15, 2026 | 2.29M | 7.43% | -8% | 434,690 | 5.3 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
CONMED company events
CONMED filed 12 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership). The latest was on Oct 28, 2026.
- Oct 28, 2026ResultsReleased financial results. Filing
- Jul 29, 2026ResultsReleased financial results. Filing
- Jun 17, 2026LeadershipCONMED Corporation announced that John E. Gallagher has been appointed to serve as the Company’s Executive Vice President, Chief Financial Officer beginning July 15, 2026. Filing
- Jun 4, 2026AgreementCONMED Corporation, a Delaware corporation, entered into separate, privately negotiated purchase agreements with certain holders of its 2.25% Convertible Senior Notes due 2027. Filing
- Jun 1, 2026AgreementCONMED Corporation, a Delaware corporation entered into the First Omnibus Amendment and Increased Facility Activation Notice, among CONMED and its subsidiary Linvatec Nederland B.V., a Netherlands private limited company ( besloten vennootschap ), as borrowers; certain of CONMED’s other… Filing
- May 20, 2026LeadershipThe Board of Directors of CONMED Corporation increased the size of the Board to nine directors and appointed Celine Martin and Jeff Mirviss as directors, each effective July 1, 2026. Filing
- Apr 29, 2026ResultsReleased financial results. Filing
- Mar 13, 2026LeadershipCONMED Corporation announced that Andrew Moller, age 51, will be appointed Interim Principal Financial Officer of the Company effective March 15, 2026. Filing
- Jan 28, 2026ResultsReleased financial results. Filing
- Jan 12, 2026AnnouncementShared information with investors. Filing
- Jan 8, 2026LeadershipCONMED Corporation announced the separation of Mr. Todd Garner, the Company’s Chief Financial Officer, effective on the earlier of March 15, 2026 or the date on which the Company appoints a new permanent CFO. Filing
- Dec 5, 2025AnnouncementShared information with investors. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
CONMED financials
Famous investors that hold CNMD
4 of the 50 well-known investors we track reported holding CNMD in their latest 13F filing. The largest position is Ken Griffin's, worth $32.6M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 705,883 | $32.6M | 0.0% | +396% |
| Israel Englander · Millennium Management | Q3 2026 | 135,087 | $6.2M | 0.0% | +18% |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 30,208 | $1.4M | 0.0% | +30% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 20,455 | $946K | 0.0% | -71% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named CNMD in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | FULLER & THALER ASSET MANAGEMENT, INC. | 13G/A | 4.9% |
| Nov 16, 2026 | FULLER & THALER ASSET MANAGEMENT, INC. | 13G/A | 4.9% |
Questions about CONMED Corp (CNMD) stock
Who owns the most CNMD stock?
The largest reported owner of CONMED Corp (CNMD) is BlackRock, Inc., with 15.6% of the company. In total, 245 funds and institutions reported holding CNMD at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are CNMD insiders buying or selling?
In the last 12 months, CNMD insiders reported no open-market purchases and 1 sale worth $10.6K. The latest trade was on Nov 21, 2025. See every trade.
What is the short interest in CNMD?
As of Oct 30, 2026, 1.86M CNMD shares were sold short, 6.2% of the shares outstanding, down 2.7% from the report before. At the average daily volume of 433,661 shares, buying them all back would take about 4.3 trading days (days to cover). See the history.
Which famous investors hold CNMD?
4 of the 50 well-known investors we track reported CNMD in their latest 13F filing, including Ken Griffin, Israel Englander, Paul Tudor Jones. The largest position is worth $32.6M. See all holders.
Executive pay
CONMED's chief executive was paid a total of $7.6M for the year ended Dec 31, 2025, up 4% from $7.4M the year before. In the last 12 months, CONMED's executives and directors bought no stock on the open market and sold $10.6K.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.